Switzerland is widely praised for its excellent universal healthcare system and strong pharma sector. Seen as a bastion of efficiency and innovation, the country is nonetheless falling behind its European…
The lowest spender on healthcare as a percentage of GDP in mainland Latin America. A complex and fragmented reimbursement system. Clinical trial approval delays stretching across eight months. One could…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
At the 13th annual meeting of French life sciences think tank, G5 Santé – which represents the leaders of eight major French health and life sciences companies, including bioMérieux, Sanofi,…
Troubled gene sequencing firm Illumina has announced a new strategy to accelerate growth. Under the leadership of CEO Jacob Thaysen, Illumina hopes to turn the page on a recent history…
This year’s European Society of Medical Oncology (ESMO) was the largest ever. Over 33,000 people attended ESMO Congress 2024 at Barcelona’s cavernous Fira Gran Via conference centre, where 5,000 abstracts…
In his latest opinion piece, Shawview Consulting’s Brendan Shaw draws from classic sci-fi to reflect on the pros and cons of using artificial intelligence for health technology assessment. Shaw concludes…
Contract research organisations (CROs) have proven to be increasingly vital partners for the global biopharmaceutical industry guaranteeing efficient and compliant clinical trials that help to advance their candidates towards regulatory…
A roundup of some of the biggest China pharma industry stories, including the progress of the US Biosecure Act targeting Chinese biotechs; Innovent’s obesity and type 2 diabetes contender’s positive…
Against the backdrop of a global push to make healthcare more accessible and affordable, ISPOR CEO and executive director Rob Abbott introduces the organisation’s 2030 strategy, focused on achieving health…
Contributing to the September 2024 edition of DIA’s Global Forum magazine, Siva Kumar Buddha of Indegene reviews the challenges of risk communication and minimization in India’s healthcare sector. In…
AstraZeneca’s Anna Litsiou, Carolyn Hynes and Allison Guy, contributing to the September 2024 edition of DIA’s Global Forum magazine, discuss the importance of improving interactions between health technology assessment (HTA)…
See our Cookie Privacy Policy Here
